Abeona’s new Form 483 is an­oth­er man­u­fac­tur­ing set­back for its rare skin con­di­tion as­set

Abeona Ther­a­peu­tics was hand­ed a Form 483 “re­lat­ed to process con­trols” for its epi­der­mol­y­sis bul­losa can­di­date in a sec­ond man­u­fac­tur­ing-re­lat­ed road­block for the pro­gram, with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER